RxDoctor Payments Data

Alissa Kincel

Adult Health · Kennett Square, PANPI 1992492524

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 63 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$309
  • Amgen$255
  • Pfizer$226
  • Impulse Dynamics (USA) Inc.$180
  • Medtronic$148
  • E.r. Squibb & Sons, L.L.C.$134
  • plus $502 from 9 others

What the payments were for

  • Food & beverage$1,754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754 in reported general payments places this provider in the 75th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$17,433
Medicare patients
300
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$123,361
Repatha SureclickEvolocumab30$28,609
EntrestoSacubitril/Valsartan20$28,203
XareltoRivaroxaban18$24,373
Metoprolol Succinate158$2,612
Rosuvastatin Calcium127$1,997
Amlodipine Besylate119$1,135
Valsartan48$1,028
Ezetimibe47$909
Atorvastatin Calcium86$856
Losartan Potassium71$686
Carvedilol49$516
Furosemide88$516
Torsemide12$459
Lisinopril63$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$226$123,36189 claims
NovartisEntresto$309$28,20320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Kennett Square

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →